Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Combination therapy for high-risk MDS? Not quite yet

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.12.14
Views: 2328
Rating:

Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA

Adding a second agent to azacitidine for older patients with high-risk myelodysplastic syndrome (MDS) was not found to improve outcomes in the North American Intergroup MDS study, according to Dr Sekeres who talked to ecancertv at ASH 2014 about this phase II randomised trial.

The trial had three arms: azacitidine monotherapy, azacitidine with lenolidomide, and azacitidine with vorinostat.

While no significant benefit emerged, Sekeres believes that dose changes and subgroups could explain this lack of response and suggests that combinations should continue to be investigated.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation